Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
McKinsey
Moodys
McKesson
AstraZeneca

Last Updated: January 22, 2020

DrugPatentWatch Database Preview

SYNERA Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which patents cover Synera, and when can generic versions of Synera launch?

Synera is a drug marketed by Galen Specialty and is included in one NDA. There is one patent protecting this drug.

This drug has five patent family members in five countries.

The generic ingredient in SYNERA is lidocaine; tetracaine. There are twenty-nine drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the lidocaine; tetracaine profile page.

US ANDA Litigation and Generic Entry Outlook for Synera

  Start Trial

Synera was eligible for patent challenges on December 31st, 1968.

Summary for SYNERA
Drug patent expirations by year for SYNERA
Drug Prices for SYNERA

See drug prices for SYNERA

Recent Clinical Trials for SYNERA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Linde AGN/A
Boston Children’s HospitalN/A
Northwell HealthPhase 4

See all SYNERA clinical trials

Pharmacology for SYNERA

US Patents and Regulatory Information for SYNERA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Galen Specialty SYNERA lidocaine; tetracaine PATCH;TOPICAL 021623-001 Jun 23, 2005 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for SYNERA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Galen Specialty SYNERA lidocaine; tetracaine PATCH;TOPICAL 021623-001 Jun 23, 2005   Start Trial   Start Trial
Galen Specialty SYNERA lidocaine; tetracaine PATCH;TOPICAL 021623-001 Jun 23, 2005   Start Trial   Start Trial
Galen Specialty SYNERA lidocaine; tetracaine PATCH;TOPICAL 021623-001 Jun 23, 2005   Start Trial   Start Trial
Galen Specialty SYNERA lidocaine; tetracaine PATCH;TOPICAL 021623-001 Jun 23, 2005   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Baxter
Mallinckrodt
Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.